Tweaked the format of the comparison and added Race Oncology....
CHM has more therapies, more FDA INDs, more active clinical trials and is targeting markets that are multiples of its ASX peers.....this is crazy!
CHM can therefore go 20-30X just to be comparable to its peers (excluding impact of options / dilution). My hope is that we not only get re-rated and approximate these peers, but that we leap frog them altogether! Which means we are potentially looking at 40-50X in a canter.....Just saying!!
Add to My Watchlist
What is My Watchlist?
